ZLDPF Zealand Pharma A/S

SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025

SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025

Press release – No.13 / 2025

SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025

Copenhagen, Denmark, September 11, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that it will host a Capital Markets Day in London on December 11, 2025, featuring presentations from management and external experts in obesity.

“Obesity is one of the greatest healthcare challenges of our time, and we are in the very early stages of a rapidly evolving market for weight loss therapies. With a differentiated pipeline targeting obesity and related comorbidities, strong partnerships supporting our leading programs, and a solid financial foundation, we are well positioned to realize our vision of becoming a key player in the future management of obesity.” said Adam Steensberg, President and Chief Executive Officer at Zealand Pharma.

“Zealand Pharma is now entering a catalyst-rich chapter from a position of strength. At our Capital Markets Day in December, we look forward to setting the stage for upcoming Phase 2 data with petrelintide and Phase 3 data with survodutide, while also sharing insights into our strategy on driving the next wave of innovation.”

External experts and thought leaders in the obesity field who will present alongside Zealand Pharma’s management team include Jonathan Roth, PhD, a metabolic researcher and pioneer in amylin-leptin biology; Dr. Louis Aronne, Professor of Clinical Medicine at Weill Cornell Medicine; and Dr. Carel Le Roux, Professor of Experimental Pathology at University College Dublin.

Further details regarding the time, venue, and registration logistics for investors and analysts wishing to participate in person will be provided in the coming weeks.

A live webcast will be available at . A replay of the webcast will be archived on the company’s website following the presentation.

About Zealand Pharma

Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.

Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand Pharma’s business and activities, please visit .

Contacts

Adam Lange (Investors)

Vice President, Investor Relations

Zealand Pharma

Email:

Neshat Anis Ahmadi (Investors)

Investor Relations Manager

Zealand Pharma

Email:

Anna Krassowska, PhD (Investors and Media)

Vice President, Investor Relations & Corporate Communications

Zealand Pharma

Email:

Amber Fennell, Jessica Hodgson, Sean Leous (Media)

ICR Healthcare



+44 (0) 7739 658 783



EN
11/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zealand Pharma A/S

 PRESS RELEASE

Total number of shares and voting rights in Zealand Pharma as of Septe...

Total number of shares and voting rights in Zealand Pharma as of September 30, 2025 Company announcement – No. 21 / 2025 Total number of shares and voting rights in Zealand Pharma as of September 30, 2025 Copenhagen, Denmark, September 30, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end o...

 PRESS RELEASE

Zealand Pharma appoints Rachel James-Owens as Vice President, Corporat...

Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations Press release – No. 14 / 2025 Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations Copenhagen, Denmark, September 24, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the appointment of Rachel James-Owens as Vice President, Corporate Communications & Media Relations. Rachel brings over 20 years of global...

Jacob Mekhael ... (+2)
  • Jacob Mekhael
  • Mathijs Geerts Danau

Life Sciences Conference 25 Sep 2025

KBC Securities will host its annual life sciences conference on 25 September in Brussels. The event will include 14 exciting companies, both public and private, from the BeNeLux ecosystem and beyond. In this conference note, we provide an overview of the attending companies, as well as an outlook on KBC Securities' life sciences broader coverage.

 PRESS RELEASE

Zealand Pharma increases its share capital as a result of the exercise...

Zealand Pharma increases its share capital as a result of the exercise of employee warrants Company announcement – No. 20 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, September 11, 2025 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 20,924 divided into 20,924 new shares ...

 PRESS RELEASE

SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on...

SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025 Press release – No.13 / 2025 SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025 Copenhagen, Denmark, September 11, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that it will host a Capital Markets Day in London on December 11, 2025, featuring presentations from management and external experts in obesity. “Obesity is one of ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch